Ropinirole Alternatives Compared
| Ropinirole | Pramipexole | Requip |
|
|---|
| Ropinirole | Pramipexole | Requip ropinirole |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ropinirole is used in the treatment of restless legs syndrome and Parkinson's disease; however, it may cause drowsiness which has caused some people to fall asleep while driving - do not drive if... View more |
Pramipexole is a dopamine agonist (mimics the effects of the neurotransmitter dopamine) that may be used in the treatment of Parkinson's disease and Restless Legs Syndrome. It may cause spontaneous... View more |
Prescribed for Restless Legs Syndrome, Periodic Limb Movement Disorder, Parkinson's Disease. Requip may also be used for purposes not listed in this medication guide. |
Choose a suggestion below Restless Legs Syndrome
Parkinson's Disease
Periodic Limb Movement Disorder
Popular Comparisons
|
|||||||||||||||
| More about Ropinirole | More about Pramipexole | More about Requip (ropinirole) | ||||||||||||||||
| Generic Status | ||||||||||||||||||
| Availability | ||||||||||||||||||
|
Prescription only |
Prescription only |
Prescription only |
||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Ropinirole has an average rating of 6.4 out of 10 from a total of 308 ratings on Drugs.com. 51% of reviewers reported a positive effect, while 27% reported a negative effect. |
Pramipexole has an average rating of 6.8 out of 10 from a total of 214 ratings on Drugs.com. 58% of reviewers reported a positive effect, while 26% reported a negative effect. |
Requip has an average rating of 6.0 out of 10 from a total of 115 ratings on Drugs.com. 48% of reviewers reported a positive effect, while 33% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
|
Commonly reported side effects include: syncope, dizziness, drowsiness, dyskinesia, fatigue, nausea, orthostatic hypotension, viral infection, decreased blood pressure, decreased pulse, increased pulse. See the full ropinirole side effects document. |
Commonly reported side effects include: drowsiness, visual hallucination, constipation, insomnia. See the full pramipexole side effects document. |
Common side effects include: syncope, dizziness, drowsiness, dyskinesia, fatigue, nausea, viral infection. See the full Requip side effects document. |
||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all ropinirole prices |
View all pramipexole prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||
|
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Requip, ReQuip Follow on Pack, Requip Starter Kit, ReQuip Starter Pack, Requip XL | Mirapex, Mirapex ER | Other ropinirole brands include: ReQuip Follow on Pack, Requip Starter Kit, ReQuip Starter Pack, Requip XL | ||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
6 hours |
8.9 hours |
6 hours |
||||||||||||||||
| CSA Schedule** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full Pregnancy Warnings document. |
Category C
Risk cannot be ruled out
See the full Pregnancy Warnings document. |
Category C
Risk cannot be ruled out
See the full Pregnancy Warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 294 drugs are known to interact with ropinirole:
|
A total of 251 drugs are known to interact with pramipexole:
|
A total of 294 drugs are known to interact with Requip:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
|
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
September 19, 1997 |
July 01, 1997 |
September 19, 1997 |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.